Resolor, INN-prucalopride
Prucalopride
Mechanism of Action | Motegrity™ (prucalopride) | Pediatric patients, Renal disease, Abdominal distension
Prucalopride
Prucalopride
Optimal management of constipation associated with irritable bowel syn | TCRM
Chronic constipation and treatment options (Review)
Prucalopride
Prucalopride | CAS:179474-81-8 | 5-HT4A and 5-HT4B receptor agonist | High Purity | Manufacturer BioCrick
Genotoxicity and carcinogenicity risk assessment of prucalopride, a selective 5-hydroxytryptamine 4 receptor agonist - ScienceDirect
Prucalopride
Proposed mechanism of action of linaclotide. GC-C, guanylate cyclase... | Download Scientific Diagram
Cureus | Role of Prucalopride in Treating Functional Constipation and Gastroparesis: A Systemic Review
Frontiers | Luminally Acting Agents for Constipation Treatment: A Review Based on Literatures and Patents | Pharmacology
Prucalopride succinate (Resolor) | New Drug Approvals
Review of efficacy and safety of laxatives use in geriatrics. - Abstract - Europe PMC
Enteric neuroplasticity and dysmotility in inflammatory disease: key players and possible therapeutic targets | American Journal of Physiology-Gastrointestinal and Liver Physiology
Review article: linaclotide for the management of irritable bowel syndrome with constipation - Layer - 2014 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Chronic constipation: Practical approaches and novel therapies | GI and Hepatology News
Action mechanism of prokinetic agents in gastrointestinal tract. | Download Scientific Diagram
Prucalopride
Review of efficacy and safety of laxatives use in geriatrics. - Abstract - Europe PMC
Prucalopride
Existing and emerging therapies for managing constipation and diarrhea - ScienceDirect
Prucalopride
Genotoxicity and carcinogenicity risk assessment of prucalopride, a selective 5-hydroxytryptamine 4 receptor agonist - ScienceDirect
